Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer γ-secretase modulators

Journal of Medicinal Chemistry

Volumn 49, Issue 26, 2006, Pages 7588-7591

  Narlawar, Rajeshwar ^a   Revuelta, Blanca I Pérez ^b   Haass, Christian ^b   Steiner, Harald ^b   Schmidt, Boris ^a   Baumann, Karlheinz ^c  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; BMS 299897; CARPROFEN; CARPROFEN DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IBUPROFEN; INDOMETACIN; SULINDAC SULFIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CONCENTRATION RESPONSE; DERIVATIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; LIPOPHILICITY; PROTEIN DEGRADATION; PROTEIN PROCESSING; STRUCTURE ANALYSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARBAZOLES; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INDOMETHACIN; NITROBENZENES; PEPTIDE FRAGMENTS; SULFONAMIDES;

EID: 33845931855     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0610200     Document Type: Article

References (27)

1. Haass, C. Take Five-BACE and the γ-Secretase Quartet Conduct Alzheimer's Amyloid β-Peptide Generation. EMBO J. 2004, 23, 483-488.
2. Churcher, I.; Beher, D. γ-Secretase as a Therapeutic Target for the Treatment of Alzheimer's Disease. Curr. Pharm. Des. 2005, 11, 3363-3382.
3. 42 Independently of Cyclooxygenase Activity. Nature 2001, 414, 212-216.
4. 42-Lowering Nonsteroidal Anti-Inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain. J. Biol. Chem. 2003, 278, 30748-30754.
5. 42 in Vivo. J. Clin. Invest. 2003, 112, 440-449.
6. 42 Generation. J. Biol. Chem. 2003, 278, 18664-18670.
7. Beher, D.; Clarke, E. E.; Wrigley, J. D. J.; Martin, A. C. L.; Nadin, A.; Churcher, I.; Shearman, M. S. Selected Non-Steroidal Anti-Inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site: Evidence for an Allosteric Mechanism. J. Biol. Chem. 2004, 279, 43419-43426.
8. in 't Veld, B. A.; Ruitenberg, A.; Hofman, A.; Launer, L. J.; van Duijn, C. M.; Stijnen, T.; Breteler, M. M. B.; Stricker, B. H. C. Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease. N. Engl. J. Med. 2001, 345, 1515-1521.
9. Aisen, P. S.; Schafer, K. A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K. L.; Farlow, M. R.; Jin, S.; Thomas, R. G.; Thai, L. J. Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial. J. Am. Med. Assoc. 2003, 289, 2819-2826.
10. Reines, S. A.; Block, G. A.; Morris, J. C.; Liu, G.; Nessly, M. L.; Lines, C. R.; Norman, B. A.; Baranak, C. C. Rofecoxib: No Effect on Alzheimer's Disease in a 1-Year, Randomized, Blinded, Controlled Study. Neurology 2004, 62, 66-71.
11. Cummings, J. L. Continuing Medical Education: Alzheimer's Disease. N. Engl. J. Med. 2004, 351, 110.
12. 42 and Change Presenilin 1 Conformation. Nat. Med. 2004, 10, 1065-1066.
13. 42 Production. Nat. Med. 2005, 11, 545-550.
14. 1-42 Secretion. J. Med. Chem. 2005, 48, 5705-5720.
15. Lanz, T. A.; Fici, G. J.; Merchant, K. M. Lack of Specific Amyloid-beta(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures. J. Pharmacol. Exp. Ther. 2005, 312, 399-406.
16. 42 Levels and Amyloid Pathology by NSAIDS and Related Compounds. Alzheimer's and Dementia 2006, 2, S601-S602.
17. Stock, N.; Munoz, B.; Wrigley, J. D. J.; Shearman, M. S.; Beher, D.; Peachey, J.; Williamson, T. L.; Bain, G.; Chen, W.; Jiang, X.; St-Jacques, R.; Prasit, P. The Geminal Dimethyl Analogue of Flurbiprofen as a Novel Aβ42 Inhibitor and Potential Alzheimer's Disease Modifying Agent. Bioorg. Med. Chem. Lett. 2006, 16, 2219-2223.
18. Ricketts, A. P.; Lundy, K. M.; Seibel, S. B. Evaluation of Selective Inhibition of Canine Cyclooxygenase 1 and 2 by Carprofen and Other Nonsteroidal Anti-Inflammatory Drugs. Am. J. Vet. Res. 1998, 59, 1441-1446.
19. Barten, D. M.; Guss, V. L.; Corsa, J. A.; Loo, A.; Hansel, S. B.; Zheng, M.; Munoz, B.; Srinivasan, K.; Wang, B.; Robertson, B. J.; Polson, C. T.; Wang, J.; Roberts, S. B.; Hendrick, J. P.; Anderson, J. J.; Loy, J. K.; Denton, R.; Verdoorn, T. A.; Smith, D. W.; Felsenstein, K. M. Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor. J. Pharmacol. Exp. Ther. 2005, 312, 635-643.
20. Beher, D.; Bettati, M.; Checksfield, G. D.; Churcher, I.; Doughty, V. A.; Oakley, P. J.; Quddus, A.; Teall, M. R.; Wrigley, J. D. Preparation of Tetrahydrocarbazole-1-Alkanoic Acids for the Treatment of Alzheimer's Disease and Related Conditions. WO 2005013985.
21. Selkoe, D.; Kopan, R. Notch and Presenilin: Regulated Intramembrane Proteolysis Links Development and Degeneration. Annu. Rev. Neurosci. 2003, 26, 565-597.
22. Kopan, R.; Ilagan, M. X. γ-Secretase: Proteasome of the Membrane? Nat. Rev. Mol. Cell Biol. 2004, 5, 499-504.
23. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. J. Med. Chem. 2000, 43, 3714-3717.
24. Sastre, M.; Steiner, H.; Fuchs, K.; Capell, A.; Multhaup, G.; Condron, M. M.; Teplow, D. B.; Haass, C. Presenilin-Dependent γ-Secretase Processing of β-Amyloid Precursor Protein at a Site Corresponding to the S3 Cleavage of Notch. EMBO J. 2001, 2, 835-841.
25. Larbig, G.; Zall, A.; Schmidt, B. Inhibitors Designed for Presenilin 1 Utilizing by Means of Aspartic Acid Activation. Helv. Chim. Acta 2004, 87, 2334-2340.
26. Boehm, H.-J., Schneider, G., Eds.; Virtual Screening for Bioactive Molecules; Wiley-VCH: Weinheim, Germany, 2000.
27. Brockhaus, M.; Grunberg, J.; Rohrig, S.; Loetscher, H.; Wittenburg, N.; Baumeister, R.; Jacobsen, H.; Haass, C. Caspase-Mediated Cleavage Is Not Required for the Activity of Presenilins in Amyloidogenesis and NOTCH Signaling. NeuroReport 1998, 9, 1481-1486.